Gain Therapeutics Statistics
Share Statistics
Gain Therapeutics has 29.56M
shares outstanding. The number of shares has increased by 46.94%
in one year.
| Shares Outstanding | 29.56M |
| Shares Change (YoY) | 46.94% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 7.48% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 39 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 295.78K, so 1.12% of the outstanding
shares have been sold short.
| Short Interest | 295.78K |
| Short % of Shares Out | 1.12% |
| Short % of Float | 1.17% |
| Short Ratio (days to cover) | 1.06 |
Valuation Ratios
The PE ratio is -2.42 and the forward
PE ratio is -2.17.
Gain Therapeutics's PEG ratio is
0.05.
| PE Ratio | -2.42 |
| Forward PE | -2.17 |
| PS Ratio | 0 |
| Forward PS | 2.4 |
| PB Ratio | 6.73 |
| P/FCF Ratio | -2.62 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Gain Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.97,
with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.97 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-887,443.09 |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 536.82K |
| Effective Tax Rate | -2.7% |
Stock Price Statistics
The stock price has increased by -26.14% in the
last 52 weeks. The beta is 0.17, so Gain Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.17 |
| 52-Week Price Change | -26.14% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 42.63 |
| Average Volume (20 Days) | 274,523 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.35M |
| Net Income | -20.41M |
| EBITDA | -19.79M |
| EBIT | -19.87M |
| Earnings Per Share (EPS) | -0.89 |
Full Income StatementBalance Sheet
The company has 10.39M in cash and 653.01K in
debt, giving a net cash position of 9.73M.
| Cash & Cash Equivalents | 10.39M |
| Total Debt | 653.01K |
| Net Cash | 9.73M |
| Retained Earnings | -81.19M |
| Total Assets | 11.62M |
| Working Capital | 6.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -18.87M
and capital expenditures -22.49K, giving a free cash flow of -18.9M.
| Operating Cash Flow | -18.87M |
| Capital Expenditures | -22.49K |
| Free Cash Flow | -18.9M |
| FCF Per Share | -0.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
